BioSpace News Archive

SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”) today announced it has signed an agreement with the Soroka University Medical Center, in Be’er-Sheva, Israel (“Soroka Medical Center”) to conduct the Company’s clinical study for SCI-210 in patients suffering from autism spectrum disorder (“ASD”).

HTG Molecular Diagnostics, Inc. provided an update on the progress of its drug discovery business unit, including the filing of a patent application directed towards its first therapeutics target, and announced that its management team will be hosting in-person meetings at the LifeSci Partners 2023 Corporate Access Event from January 9-11, 2023 in San Francisco, CA.

Nurix Therapeutics, Inc. today outlined key objectives and anticipated milestones for 2023 and provided an overview of recent progress in a presentation at the 41st Annual J.P. Morgan Healthcare Conference.

Kintara Therapeutics, Inc. today announced that Robert E. Hoffman , President and CEO of Kintara, will be presenting at the Biotech Showcase Conference in San Francisco.

Biobeat announced today that its wearable remote patient monitoring devices have received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to monitor stroke volume and cardiac output in addition to cuffless blood pressure, blood oxygen saturation, pulse rate, respiratory rate and body temperature.

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today highlights progress in its acute care and oncology care franchises.

Pancreatic adenocarcinoma is a malignancy with an extremely poor prognosis and high fatality rate. Despite advances in medical technologies over the past decades, early detection and effective treatments are limited.

Outset Medical, Inc. today reported expected revenue for the fourth quarter and fiscal year ended December 31, 2022.

Quanterix Corporation (NASDAQ: QTRX) today announced the validation of a Laboratory Developed Test (LDT) to quantitatively measure neurofilament light chain (NfL) in serum as an aid in the evaluation of individuals for possible neurodegenerative conditions or other causes of neuronal or central nervous system damage.

Legend Biotech Corporation announced today that it received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on January 6, 2023 indicating that the Company is not currently in compliance with Nasdaq’s Listing Rules.